V. Srimuninnimit

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of three gemcitabine (GEM)-taxane combinations in metastatic breast cancer (MBC.

M. Lehnert, A. Bustam, V. Srimuninnimit, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2014, European journal of cancer.

Ketoconazole and Flutamide in the treatment of disseminated intravascular clotting from prostate cancer: a case report and review.

V. Srimuninnimit, S. Chakrapee-sirisuk, K. Amornpichetkul, 2001, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors

A. Chuansumrit, V. Srimuninnimit, N. Sriudomporn, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

J. Blay, G. Demetri, Yoon-Koo Kang, 2015, The Lancet. Oncology.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

T. Mok, I. Bondarenko, B. Karaszewska, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study

H. Harling, V. Srimuninnimit, S. Larsen, 2019, Breast cancer.

Efficacy and tolerability of BP-C1 in metastatic breast cancer: a Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study

H. Harling, V. Srimuninnimit, S. Larsen, 2019, Breast cancer.

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

T. Mok, Yi-long Wu, S. Thongprasert, 2015, Clinical Cancer Research.

Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned

Dae-Ho Lee, R. Cheng, M. Orlando, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Li Zhang, Hongming Pan, Chong-Jen Yu, 2013, The Lancet. Oncology.

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

T. Mok, Yi-long Wu, Yuh-Min Chen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.

W. Gradishar, F. Cardoso, Joon Jeong, 2017 .

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

R. Gelber, J. Baselga, J. Mayordomo, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.

V. Lorvidhaya, V. Ratanatharathorn, V. Srimuninnimit, 2001, Lung cancer.

BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase

A. Manikhas, V. Srimuninnimit, M. Matrosova, 2014, Breast cancer.

Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).

R. Motzer, K. Pittman, C. Barrios, 2015 .

Ewing's sarcoma and primitive neuroectodermal tumour (ES/PNET) presenting as a breast mass.

V. Srimuninnimit, M. Warnnissorn, W. Prasert, 2012, Oncology letters.

Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil

G. Wampler, V. Srimuninnimit, 2004, Cancer Chemotherapy and Pharmacology.

Autoantibody profiles and clinical association in Thai patients with autoimmune retinopathy

L. Atchaneeyasakul, V. Srimuninnimit, A. Koolvisoot, 2021, Scientific Reports.

Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study

V. Srimuninnimit, P. Danchaivijitr, N. Soparattanapaisarn, 2017, Supportive Care in Cancer.

Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).

A. Lluch, V. Semiglazov, Y. Im, 2015 .

C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).

V. Srimuninnimit, A. Nimmannit, N. Soparattanapaisarn, 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.

M. Schlichting, J. Douillard, J. Heighway, 2014, Clinical colorectal cancer.

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.

Chun-Ming Tsai, J. Yang, Jin-Hyoung Kang, 2016, Clinical lung cancer.

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

M. Piccart, G. Hortobagyi, J. Baselga, 2014 .

A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II.

T. Mok, Yi-long Wu, S. Thongprasert, 2012 .

Symptom Clusters and Quality of Life in Women with Breast Cancer Receiving Adjuvant Chemotherapy

C. Viwatwongkasem, Tiraporn Junda, V. Srimuninnimit, 2013 .

A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer.

V. Srimuninnimit, A. Ratanawichitrasin, P. O-Charoenrat, 2010, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer

L. Shen, R. Xu, H. Pan, 2016 .

Association between estrogen receptor concentration in breast cancer tissue and bone mineral density.

V. Srimuninnimit, S. Sriussadaporn, S. Chearskul, 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Benzene-Poly-Carboxylic Acids Complex with Cis-Diammineplatinum (II) Dichloride in the Treatment of Stage IV Breast Cancer Patients

Yen-Shen Lu, V. Srimuninnimit, S. Larsen, 2013 .

Clinical management and resolution of stomatitis in BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): Initial results from the East/South East (E/SE) Asian subgroup

Keunchil Park, Yi-long Wu, H. Kuo, 2007 .

Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open‐label, single‐arm phase II study

V. Sriuranpong, V. Srimuninnimit, S. Suwanvecho, 2014, Asia-Pacific journal of clinical oncology.

Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.

G. Hortobagyi, J. Baselga, H. Rugo, 2013 .

FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC

T. Mok, B. Karaszewska, K. Kubota, 2021 .

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

R. Motzer, K. Pittman, C. Barrios, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.

M. Schlichting, J. Douillard, J. Heighway, 2014, Clinical colorectal cancer.

363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer

Yi-long Wu, T. Mok, B. Karaszewska, 2021, Journal for ImmunoTherapy of Cancer.